These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 20381364

  • 1. Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies.
    Pawar V, Lokwani D, Bhandari S, Mitra D, Sabde S, Bothara K, Madgulkar A.
    Bioorg Med Chem; 2010 May 01; 18(9):3198-211. PubMed ID: 20381364
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives.
    Bal TR, Anand B, Yogeeswari P, Sriram D.
    Bioorg Med Chem Lett; 2005 Oct 15; 15(20):4451-5. PubMed ID: 16115762
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.
    Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E.
    Bioorg Med Chem; 2007 May 01; 15(9):3134-42. PubMed ID: 17349793
    [Abstract] [Full Text] [Related]

  • 6. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase.
    Carlsson J, Boukharta L, Aqvist J.
    J Med Chem; 2008 May 08; 51(9):2648-56. PubMed ID: 18410085
    [Abstract] [Full Text] [Related]

  • 7. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
    Kireev DB, Chrétien JR, Grierson DS, Monneret C.
    J Med Chem; 1997 Dec 19; 40(26):4257-64. PubMed ID: 9435895
    [Abstract] [Full Text] [Related]

  • 8. QSAR study of isatin analogues as in vitro anti-cancer agents.
    Sabet R, Mohammadpour M, Sadeghi A, Fassihi A.
    Eur J Med Chem; 2010 Mar 19; 45(3):1113-8. PubMed ID: 20056518
    [Abstract] [Full Text] [Related]

  • 9. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
    Li Z, Han J, Chen HF.
    Chem Biol Drug Des; 2008 Nov 19; 72(5):350-9. PubMed ID: 19012571
    [Abstract] [Full Text] [Related]

  • 10. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents.
    Chen KX, Xie HY, Li ZG, Gao JR.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5381-6. PubMed ID: 18835162
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).
    Lavecchia A, Costi R, Artico M, Miele G, Novellino E, Bergamini A, Crespan E, Maga G, Di Santo R.
    ChemMedChem; 2006 Dec 15; 1(12):1379-90. PubMed ID: 17089434
    [Abstract] [Full Text] [Related]

  • 13. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
    Ragno R, Mai A, Sbardella G, Artico M, Massa S, Musiu C, Mura M, Marturana F, Cadeddu A, La Colla P.
    J Med Chem; 2004 Feb 12; 47(4):928-34. PubMed ID: 14761194
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Lagos CF, Caballero J, Gonzalez-Nilo FD, David Pessoa-Mahana C, Perez-Acle T.
    Chem Biol Drug Des; 2008 Nov 12; 72(5):360-9. PubMed ID: 19012572
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Di Santo R, Costi R, Artico M, Ragno R, Lavecchia A, Novellino E, Gavuzzo E, La Torre F, Cirilli R, Cancio R, Maga G.
    ChemMedChem; 2006 Jan 12; 1(1):82-95. PubMed ID: 16892340
    [Abstract] [Full Text] [Related]

  • 18. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
    Mandal AS, Roy K.
    Eur J Med Chem; 2009 Apr 12; 44(4):1509-24. PubMed ID: 18760864
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Qin H, Liu C, Guo Y, Wang R, Zhang J, Ma L, Zhang Z, Wang X, Cui Y, Liu J.
    Bioorg Med Chem; 2010 May 01; 18(9):3231-7. PubMed ID: 20371182
    [Abstract] [Full Text] [Related]

  • 20. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
    Ragno R, Artico M, De Martino G, La Regina G, Coluccia A, Di Pasquali A, Silvestri R.
    J Med Chem; 2005 Jan 13; 48(1):213-23. PubMed ID: 15634015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.